{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:06:05Z","timestamp":1794017165339,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Tolvaptan, a selective vasopressin V2-receptor antagonist, is approved for the treatment of SIADH-related hyponatremia, but its use is limited. The starting dose is usually 15\u2009mg\/day, but recent clinical experience suggests a lower starting dose (&lt;15\u2009mg\/day) to reduce the risk of sodium overcorrection. However, long-term low-dose efficacy and safety has not been explored, so far. Aim of our study is to characterize safety and efficacy of long-term SIADH treatment with low-dose Tolvaptan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively evaluated 11 patients receiving low-dose Tolvaptan (&lt;15\u2009mg\/day) for chronic SIADH due to neurological, idiopathic and neoplastic causes. Plasma sodium levels were measured before and 1, 3, 5, 15 and 30 days after starting Tolvaptan and then at 3-month intervals. Anamnestic and clinical data were collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean time spanned 27.3\u2009\u00b1\u200929.8 months (range 6 months-7\u2009years). Mean plasma sodium levels were within normal range 1, 3 and 6 months after starting Tolvaptan as well as after 1, 2, 3, 5 and 7 years of therapy. Neither osmotic demyelination syndrome nor overcorrection were observed. Plasma sodium levels normalization was associated with beneficial clinical effects. Neurological patients obtained seizures disappearance, improvement in neurological picture and good recovery from rehabilitation. Neoplastic patients were able to start chemotherapy and improved their general condition. Patients did not show hypernatremia during long-term follow-up and reported mild thirst and pollakiuria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present study shows that long-term low-dose Tolvaptan is safe and effective in SIADH treatment. No cases of overcorrection were documented and mild side effects were reported.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-023-03457-w","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T17:01:49Z","timestamp":1690563709000},"page":"390-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long-term low-dose tolvaptan efficacy and safety in SIADH"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8071-6559","authenticated-orcid":false,"given":"Marta","family":"Bondanelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9261-8593","authenticated-orcid":false,"given":"Ludovica","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3280-8592","authenticated-orcid":false,"given":"Irene","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-9770","authenticated-orcid":false,"given":"Maria Rosaria","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-7796","authenticated-orcid":false,"given":"Maria Chiara","family":"Zatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"issue":"20","key":"3457_CR1","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"R.W. Schrier, P. Gross, M. Gheorghiade, T. Berl, J.G. Verbalis, F.S. Czerwiec, C. Orlandi; SALT Investigators, Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355(20), 2099\u20132112 (2006). https:\/\/doi.org\/10.1056\/NEJMoa065181","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"3457_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/2042018812437561","volume":"3","author":"P Gross","year":"2012","unstructured":"P. Gross, Clinical management of SIADH. Ther. Adv. Endocrinol. Metab. 3(2), 61\u201373 (2012). https:\/\/doi.org\/10.1177\/2042018812437561","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"8","key":"3457_CR3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/eci.12465","volume":"45","author":"P Grant","year":"2015","unstructured":"P. Grant, J. Ayuk, P.M. Bouloux, M. Cohen, I. Cranston, R.D. Murray, A. Rees, N. Thatcher, A. Grossman, The diagnosis and management of inpatient hyponatraemia and SIADH. Eur. J Clin. Investig. 45(8), 888\u2013894 (2015). https:\/\/doi.org\/10.1111\/eci.12465","journal-title":"Eur. J Clin. Investig."},{"issue":"11","key":"3457_CR4","doi-asserted-by":"publisher","first-page":"e4766","DOI":"10.1210\/clinem\/dgab131","volume":"106","author":"V Chatzimavridou-Grigoriadou","year":"2021","unstructured":"V. Chatzimavridou-Grigoriadou, S. Al-Othman, G. Brabant, A. Kyriacou, J. King, F. Blackhall, P.J. Trainer, C.E. Higham, Clinical experience of the efficacy and safety of low-dose tolvaptan therapy in a UK tertiary oncology setting. J. Clin. Endocrinol. Metab. 106(11), e4766\u2013e4775 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab131","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3457_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.xkme.2019.09.004","volume":"2","author":"RM Hanna","year":"2019","unstructured":"R.M. Hanna, J.C. Velez, A. Rastogi, M.K. Nguyen, M.K. Kamgar, K. Moe, F. Arman, H. Hasnain, N. Nobakht, U. Selamet, I. Kurtz, Equivalent efficacy and decreased rate of overcorrection in patients with syndrome of inappropriate secretion of antidiuretic hormone given very low-dose tolvaptan. Kidney Med. 2(1), 20\u201328 (2019). https:\/\/doi.org\/10.1016\/j.xkme.2019.09.004","journal-title":"Kidney Med."},{"issue":"3","key":"3457_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12020-016-0912-y","volume":"53","author":"B Harbeck","year":"2016","unstructured":"B. Harbeck, U. Lindner, C.S. Haas, Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH). Endocrine 53(3), 872\u2013873 (2016). https:\/\/doi.org\/10.1007\/s12020-016-0912-y","journal-title":"Endocrine"},{"issue":"52","key":"3457_CR7","doi-asserted-by":"publisher","first-page":"e9539","DOI":"10.1097\/MD.0000000000009539","volume":"96","author":"YH Liu","year":"2017","unstructured":"Y.H. Liu, X.B. Han, Y.H. Fei, H.T. Xu, Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremia: report on safety and effectiveness. Medicine 96(52), e9539 (2017). https:\/\/doi.org\/10.1097\/MD.0000000000009539","journal-title":"Medicine"},{"issue":"3","key":"3457_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/jcm6030028","volume":"6","author":"S B\u00fcttner","year":"2017","unstructured":"S. B\u00fcttner, J. Bachmann, H. Geiger, N. Oberm\u00fcller, Long-term vaptan treatment of idiopathic SIADH in an octogenarian. J. Clin. Med. 6(3), 28 (2017). https:\/\/doi.org\/10.3390\/jcm6030028","journal-title":"J. Clin. Med."},{"issue":"4","key":"3457_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2009080857","volume":"21","author":"T Berl","year":"2010","unstructured":"T. Berl, F. Quittnat-Pelletier, J.G. Verbalis, R.W. Schrier, D.G. Bichet, J. Ouyang, F.S. Czerwiec; SALTWATER Investigators, Oral tolvaptan is safe and effective in chronic hyponatremia. J. Am. Soc. Nephrol. 21(4), 705\u2013712 (2010). https:\/\/doi.org\/10.1681\/ASN.2009080857","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"3457_CR10","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-13-1020","volume":"170","author":"G Spasovski","year":"2014","unstructured":"G. Spasovski, R. Vanholder, B. Allolio, D. Annane, S. Ball, D. Bichet, G. Decaux, W. Fenske, E.J. Hoorn, C. Ichai, M. Joannidis, A. Soupart, R. Zietse, M. Haller, S. van der Veer, W. Van Biesen, E. Nagler; Hyponatraemia Guideline Development Group, Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur. J. Endocrinol. 170(3), G1\u2013G47 (2014). https:\/\/doi.org\/10.1530\/EJE-13-1020","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"3457_CR11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1089\/neu.2007.0343","volume":"24","author":"M Bondanelli","year":"2007","unstructured":"M. Bondanelli, M.R. Ambrosio, L. Cavazzini, A. Bertocchi, M.C. Zatelli, A. Carli, D. Valle, N. Basaglia, E.C. Uberti, Anterior pituitary function may predict functional and cognitive outcome in patients with traumatic brain injury undergoing rehabilitation. J. Neurotrauma 24(11), 1687\u20131697 (2007). https:\/\/doi.org\/10.1089\/neu.2007.0343","journal-title":"J. Neurotrauma"},{"issue":"6","key":"3457_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, E.T. McFadden, P.P. Carbone, Toxicity and response criteria of the eastern cooperative oncology group. Am. J. Clin. Oncol. 5(6), 649\u2013655 (1982)","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"3457_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1681\/ASN.2016101139","volume":"28","author":"EJ Hoorn","year":"2017","unstructured":"E.J. Hoorn, R. Zietse, Diagnosis and treatment of hyponatremia: compilation of the guidelines. J. Am. Soc. Nephrol. 28(5), 1340\u20131349 (2017). https:\/\/doi.org\/10.1681\/ASN.2016101139","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"3457_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00520-015-2948-6","volume":"24","author":"R De Las Pe\u00f1as","year":"2016","unstructured":"R. De Las Pe\u00f1as, S. Ponce, F. Henao, C. Camps Herrero, E. Carcereny, Y. Escobar \u00c1lvarez, C.A. Rodr\u00edguez, J.A. Virizuela, R. L\u00f3pez L\u00f3pez, SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan. Supportive Care Cancer 24(1), 499\u2013507 (2016). https:\/\/doi.org\/10.1007\/s00520-015-2948-6","journal-title":"Supportive Care Cancer"},{"issue":"2","key":"3457_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s0889-8529(03)00004-5","volume":"32","author":"N Janicic","year":"2003","unstructured":"N. Janicic, J.G. Verbalis, Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol. Metab. Clin. N. Am. 32(2), 459\u2013vii (2003). https:\/\/doi.org\/10.1016\/s0889-8529(03)00004-5","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"issue":"19","key":"3457_CR16","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","volume":"111","author":"L Klein","year":"2005","unstructured":"L. Klein, C.M. O\u2019Connor, J.D. Leimberger, W. Gattis-Stough, I.L. Pi\u00f1a, G.M. Felker, K.F. Adams Jr, R.M. Califf, M. Gheorghiade; OPTIME-CHF Investigators, Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111(19), 2454\u20132460 (2005). https:\/\/doi.org\/10.1161\/01.CIR.0000165065.82609.3D","journal-title":"Circulation"},{"issue":"1","key":"3457_CR17","doi-asserted-by":"publisher","first-page":"71.e1","DOI":"10.1016\/j.amjmed.2005.09.026","volume":"119","author":"B Renneboog","year":"2006","unstructured":"B. Renneboog, W. Musch, X. Vandemergel, M.U. Manto, G. Decaux, Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am. J. Med. 119(1), 71.e1\u201371.e718 (2006). https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.026","journal-title":"Am. J. Med."},{"issue":"2","key":"3457_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.ajkd.2011.08.029","volume":"59","author":"SM Doshi","year":"2012","unstructured":"S.M. Doshi, P. Shah, X. Lei, A. Lahoti, A.K. Salahudeen, Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am. J. Kidney Dis. 59(2), 222\u2013228 (2012). https:\/\/doi.org\/10.1053\/j.ajkd.2011.08.029","journal-title":"Am. J. Kidney Dis."},{"issue":"10 Suppl 1","key":"3457_CR19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","volume":"126","author":"JG Verbalis","year":"2013","unstructured":"J.G. Verbalis, S.R. Goldsmith, A. Greenberg, C. Korzelius, R.W. Schrier, R.H. Sterns, C.J. Thompson, Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am. J. Med. 126(10 Suppl 1), S1\u2013S42 (2013). https:\/\/doi.org\/10.1016\/j.amjmed.2013.07.006","journal-title":"Am. J. Med."},{"issue":"3","key":"3457_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.21037\/tcr-20-2123.","volume":"10","author":"P Ren","year":"2021","unstructured":"P. Ren, Q. Yang, The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases. Transl. Cancer Res. 10(3), 1229\u20131237 (2021). https:\/\/doi.org\/10.21037\/tcr-20-2123.","journal-title":"Transl. Cancer Res."},{"issue":"5","key":"3457_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1530\/EJE-10-1078","volume":"164","author":"JG Verbalis","year":"2011","unstructured":"J.G. Verbalis, S. Adler, R.W. Schrier, T. Berl, Q. Zhao, F.S. Czerwiec; SALT Investigators, Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur. J. Endocrinol. 164(5), 725\u2013732 (2011). https:\/\/doi.org\/10.1530\/EJE-10-1078","journal-title":"Eur. J. Endocrinol."},{"key":"3457_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejim.2016.07.028","volume":"36","author":"C Selmer","year":"2016","unstructured":"C. Selmer, J.C. Madsen, C. Torp-Pedersen, G.H. Gislason, J. Faber, Hyponatremia, all-cause mortality, and risk of cancer diagnoses in the primary care setting: a large population study. Eur. J. Intern. Med. 36, 36\u201343 (2016). https:\/\/doi.org\/10.1016\/j.ejim.2016.07.028","journal-title":"Eur. J. Intern. Med."},{"issue":"14","key":"3457_CR23","doi-asserted-by":"publisher","first-page":"23871","DOI":"10.18632\/oncotarget.13372","volume":"8","author":"R Berardi","year":"2017","unstructured":"R. Berardi, M. Santoni, T. Newsom-Davis, M. Caramanti, S. Rinaldi, M. Tiberi, F. Morgese, M. Torniai, M. Pistelli, A. Onofri, M. Bower, S. Cascinu, Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget 8(14), 23871\u201323879 (2017). https:\/\/doi.org\/10.18632\/oncotarget.13372","journal-title":"Oncotarget"},{"issue":"7","key":"3457_CR24","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s11739-016-1508-5","volume":"12","author":"LM Castello","year":"2017","unstructured":"L.M. Castello, M. Baldrighi, A. Panizza, E. Bartoli, G.C. Avanzi, Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the emergency department. Intern. Emerg. Med. 12(7), 993\u20131001 (2017). https:\/\/doi.org\/10.1007\/s11739-016-1508-5","journal-title":"Intern. Emerg. Med."},{"issue":"4","key":"3457_CR25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/cen.12943","volume":"84","author":"P Tzoulis","year":"2016","unstructured":"P. Tzoulis, J.A. Waung, E. Bagkeris, H. Carr, B. Khoo, M. Cohen, P.M. Bouloux, Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion. Clin. Endocrinol. 84(4), 620\u2013626 (2016). https:\/\/doi.org\/10.1111\/cen.12943","journal-title":"Clin. Endocrinol."},{"issue":"Suppl 1","key":"3457_CR26","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"M. Matsuzaki, M. Hori, T. Izumi, M. Fukunami; Tolvaptan Investigators, Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc. Drugs Ther. 25(Suppl 1), S33\u2013S45 (2011). https:\/\/doi.org\/10.1007\/s10557-011-6304-x","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"3457_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2009.05.015","volume":"68","author":"O Hansen","year":"2010","unstructured":"O. Hansen, P. S\u00f8rensen, K.H. Hansen, The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung cancer (Amsterdam, Netherlands) 68(1), 111\u2013114 (2010). https:\/\/doi.org\/10.1016\/j.lungcan.2009.05.015","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"8","key":"3457_CR28","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1210\/clinem\/dgac245","volume":"107","author":"J Martin-Grace","year":"2022","unstructured":"J. Martin-Grace, M. Tomkins, M.W. O\u2019Reilly, C.J. Thompson, M. Sherlock, Approach to the Patient: hyponatremia and the Syndrome of Inappropriate Antidiuresis (SIAD). J. Clin. Endocrinol. Metab. 107(8), 2362\u20132376 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac245","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03457-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03457-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03457-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T07:09:01Z","timestamp":1696057741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03457-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["3457"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03457-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"29 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.B., L.A., I.G., M.C.Z. and M.R.A. have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all patients to be included in the study. Approval to conduct this human subject research was obtained from the Local Ethics Committee (protocol number CE-AVEC 697\/2020\/Oss\/AOUFe). All procedures were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human studies and informed consent"}}]}}